Africa is unique, culturally diverse with various traditional practices that may play greater roles in creating the enabling environment for viral diseases, such as Ebola.
ZMapp, an experimental therapy comprising three monoclonal antibodies, has shown promise in a clinical trial, but it targets only one of the five known species of Ebola virus.
The same experimental vaccine concept being used to prevent Ebola in the Democratic Republic of the Congo (DRC) also is the basis for an experimental vaccine against Nipah
On May 8, 2018, the Democratic Republic of the Congo (DRC) reported an outbreak of Ebola virus disease—a serious and often fatal illness—in Équateur Province in the northwest part of the country. As the U.S. government’s lead agency on biomedical… Read More ›
The World Bank Group’s Pandemic Emergency Financing Facility (PEF) welcomes Australia as a donor to the PEF, joining Japan and Germany. Australia is contributing US$7.2 million to the PEF’s Cash Window, which was set up through an initial contribution from Germany. Australia… Read More ›
A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland.
The World Bank Group’s Pandemic Emergency Financing Facility (PEF) today made its first-ever financial commitment, approving a $12 million grant towards the current Ebola response in the Democratic Republic of the Congo (DRC). The grant, approved today at an emergency… Read More ›